IP Library Granted Patent US 8,975,295
Granted Patent B2
US 8,975,295 · App. 10/692,191 · Granted Mar 10, 2015

Modulation of zinc levels to improve tissue properties

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,975,295
App. No.
10/692,191
Granted
Mar 10, 2015
Kind
B2
Abstract

Methods of altering properties of tissues, by providing an effective modifying amount of zinc, which may be in the form of zinc ions. This is accomplished through the use of topical compositions containing one or more zinc-containing components such as salts and/or other zinc compounds or complexes, particularly zinc acetate. Altering properties of tissues includes increasing or decreasing fatty tissue, increasing or decreasing epidermal thickness, increasing elastin content, and preventing or treating gum regression or atrophy. Also disclosed is the provision of a contact lens coated with a zinc-containing material, to improve vision by increasing elastin content of the lens of the eye through release of zinc ions.

Claims (15)

1. A method for increasing elastin content in a region of skin of a subject that is in need of increased elastin content, the method consisting essentially of applying topically a composition consisting essentially of one or more zinc-containing components in admixture with a dermatologically acceptable carrier to the region of skin of the subject,

wherein the one or more zinc-containing components is selected from the group consisting of zinc acetate, zinc ascorbate, zinc aspartate, zinc butyrate, zinc caproate, zinc caprylate, zinc carbonate, zinc citraconate, zinc citramalate, zinc citrate, zinc EDTA, zinc formate, zinc fumarate, zinc gallate, zinc gluconate, zinc halides, zinc lactate, zinc malate, zinc maleate, zinc malonate, zinc metaphosphate, zinc monophosphate, zinc nitrate, zinc octoate, zinc orotate, zinc orthophosphate, zinc oxalate, zinc phosphate, zinc picolinate, zinc propionate, zinc pyrophosphate, zinc salicylate, zinc selenate, zinc succinate, zinc sulfate, zinc sulfonate, zinc tartrate, zinc tetrametaphosphate, zinc tripolyphosphate, zinc valerate, zinc amino acid complexes, zinc nucleotide complexes, and mixtures thereof,

wherein zinc of the said one or more zinc-containing components is present in the composition at a concentration that increases elastin without causing epidermal sloughing and irritation due to zinc,

wherein said concentration is in the range of 10 μM to 1.0 mM, and

wherein the elastin content in the region of skin is increased.

2. The method according to claim 1 , wherein the one or more zinc-containing components is zinc carbonate.

3. The method according to claim 1 , wherein the one or more zinc-containing components is comprises zinc citrate.

4. The method according to claim 1 , wherein zinc of the said one or more zinc-containing components is present in the composition at a concentration of 1.0 mM.

5. The method according to claim 2 , wherein zinc of the said one or more zinc-containing components is present in the composition at a concentration of 1.0 mM.

6. The method according to claim 3 , wherein zinc of the said one or more zinc-containing components is present in the composition at a concentration of 1.0 mM.

7. The method according to claim 1 , wherein the region of skin is selected from the group consisting of the face, breasts, buttocks, neck, legs, arms, torso, and furrows or wrinkles in the face, hands or neck.

8. The method according to claim 1 , wherein the carrier further comprises a moisturizer.

9. The method according to claim 1 , wherein zinc of the said one or more zinc-containing components is present in the composition at a concentration of 10 μM.

10. The method according to claim 2 , wherein zinc of the said one or more zinc-containing components is present in the composition at a concentration of 10 μM.

11. The method according to claim 3 , wherein zinc of the said one or more zinc-containing components is present in the composition at a concentration of 10 μM.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0864 →
SECURITY AGREEMENT Recorded Jul 6, 2015
From: ECR PHARMACEUTICALS CO., INC.; PRECISION DERMATOLOGY, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036091/0257 →
RELEASE OF SECURITY INTEREST Recorded Jul 7, 2014
From: GCI CAPITAL MARKETS, LLC
To: PRECISION DERMATOLOGY, INC.
Reel/Frame 033280/0556 →
RELEASE OF SECURITY INTEREST Recorded Sep 27, 2013
From: MIDCAP FUNDING III, LLC
To: PRECISION DERMATOLOGY COMPANY, INC.; ONSET DERMATOLOGICS, LLC; PROSKIN, LLC; PRECISION MD, LLC; TP CREAM SUB, LLC; TP LOTION SUB, LLC
Reel/Frame 031296/0492 →
SECURITY AGREEMENT Recorded Sep 20, 2013
From: PRECISION DERMATOLOGY, INC.
To: GCI CAPITAL MARKETS LLC
Reel/Frame 031249/0011 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2012
From: REVANCE THERAPEUTICS, INC.
To: PRECISION DERMATOLOGY, INC.
Reel/Frame 029043/0761 →
SECURITY AGREEMENT Recorded May 18, 2012
From: PRECISION DERMATOLOGY, INC.; ONSET DERMATOLOGICS, LLC; PROSKIN LLC; PRECISION MD LLC; TP CREAM SUB, LLC; TP LOTION SUB, LLC
To: MIDCAP FUNDING III, LLC
Reel/Frame 028234/0424 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 24432/321, 24432/284, 24432/317, 22432/187, AND 22756/549 Recorded Oct 4, 2011
From: LEADER VENTURES, LLC
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 027015/0658 →
SECURITY AGREEMENT Recorded May 29, 2009
From: REVANCE THERAPEUTICS, INC.
To: LEADER VENTURES, LLC
Reel/Frame 022756/0549 →
CHANGE OF NAME Recorded Mar 20, 2009
From: ESSENTIA BIOSYSTEMS, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 022431/0053 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2004
From: CIFRA, PAMELA; DAKE, MICHAEL D.; ELKINS, CHRISTOPHER; WAUGH, JACOB M.
To: ESSENTIA BIOSYSTEMS, INC.
Reel/Frame 014391/0286 →